On 5 Oct 2026, AGILE GROUP (03383.HK) is close to finalising an RSA for US$5.183bn of offshore debt, with ~64.6% of post-restructuring shares as consideration.
On 4 Oct 2026, BUD APAC (01876.HK) flagged ~US$82m of Q3 charges: ~US$52m reorganisation withholding tax and ~US$30m India receivables provision.
On 4 Oct 2026, LONGSYS (09976.HK) said its IPO stabilisation period ended on 3 Oct; the over-allotment option lapsed, so no more H shares will be issued.
On 2 Oct 2026, PATEO (02889.HK) completed the acquisition of a ~70% stake; the target was valued at RMB2.7bn with consideration capped at RMB1.4bn.
On 2 Oct 2026, WK GROUP (02535.HK) and WellLuck said the mandatory cash offer lapsed as conditions were unmet, with only 30,000 shares (0.0015%) accepted.
On 2 October 2026, GoFintech Quantum Innovation Limited (00290.HK) announced that its Fortune Asset Management Open-ended Fund Company and its two publicly offered sub-funds (the Fortune Asset Technology Select Equity Fund and the Fortune Asset Fixed Income Fund) were approved by the Securities and Futures Commission of Hong Kong on 30 September 2026.
On 2 October 2026, Ascletis Pharma Inc. (01672.HK) announced that key preclinical data for ASC36_35FDC were presented at the 62nd Annual Meeting of the European Association for the Study of Diabete.
As of October 2, 2026, Global X China Semiconductor ETF (03191.HK) fell 5.19% intraday to a latest price of HK$76.320, with a turnover of HK$32.2959 million; the ETF is managed by Mirae Asset Global Investments (Hong Kong) Limited and tracks the FactSet China Semiconductor Index (Net Total Return), with assets under management of HK$2.804 billion and a net asset value per unit of HK$77.99.
On 30 September 2026, ACROBIOSYSTEMS (301080.SZ) filed for a Main Board listing on HKEX, with China Merchants Securities (HK) as sole sponsor.
On 30 September 2026, Amicro Technology passed the HKEX listing hearing, with China Securities International and Guotai Junan International as joint sponsors.
On 1 October 2026, PHANCY (06682.HK) terminated its subscription agreement for new shares of Huanxi Media (01003.HK) as conditions precedent were unmet; the subscription will not proceed.
On 30 September 2026, the CSRC issued supplementary filing requirements to five companies pursuing Hong Kong listings, covering capital and compliance.
On 30 September 2026, AMLOGIC (688099.SH) completed CSRC filing for up to 53,815,500 shares to be listed on HKEX, under a notice dated 24 August 2026.
On 30 September 2026, TGOOD (300001.SZ) said it received a CSRC filing notice for an H-share offering of up to 134,847,300 shares to be listed on HKEX.
On 29 September 2026, YUDO filed for an HKEX Main Board listing with CICC and CITIC Securities as joint sponsors. It is the world's largest HRS provider.
On 30 September 2026, CSPC PHARMA reported positive Phase III results for its GLP-1 receptor agonist Efmedaglutide Alfa Injection in type 2 diabetes.
